The Rise of PROTACs and Targeted Protein Degradation Technologies

Traditional drug discovery has largely been built around a simple principle: find a pocket on a disease-relevant protein, bind it with sufficient affinity, and block its function. That strategy has produced many successful medicines, but it also leaves numerous biologically important proteins difficult to address with conventional small molecules.

Targeted protein degradation (TPD) offers a different approach. Rather than continuously occupying a binding site, degraders can recruit the cell’s own protein-disposal machinery to remove a selected protein. The best-known example is the proteolysis-targeting chimera (PROTAC), a bifunctional molecule designed to bring a target protein into proximity with an E3 ubiquitin ligase.

The idea is significant because the therapeutic objective changes from inhibiting a protein to eliminating it. Modern TPD research is therefore expanding the boundaries of drug discovery, including proteins that have historically been described as difficult or “undruggable.”

How PROTACs Work: The Mechanism of Action

A PROTAC is typically built from three functional components: a warhead that recognizes the protein of interest (POI), a ligand that recruits an E3 ubiquitin ligase, and a chemical linker connecting the two. This architecture allows the molecule to act as a proximity-inducing agent rather than simply as a conventional inhibitor.

Formation of the Ternary Complex

After entering a cell, the PROTAC simultaneously engages the POI and an E3 ligase. These interactions bring the two proteins into close proximity and create a ternary complex.

Importantly, degradation efficiency does not depend only on how tightly each individual ligand binds. The geometry and stability of the resulting POI–PROTAC–E3 complex can strongly influence whether ubiquitin is efficiently transferred to the target. Consequently, linker length, composition, attachment points and protein surfaces all become important variables during degrader optimization.

This is one reason PROTAC development can differ substantially from conventional medicinal chemistry. A compound with excellent binary binding affinity may not necessarily produce efficient degradation, while another compound with moderate individual affinities may form a productive ternary complex.

Ubiquitination and Proteasomal Degradation

Once the ternary complex is productively assembled, the E3 ligase facilitates the transfer of ubiquitin onto the target protein through the cellular ubiquitination machinery. Polyubiquitination can mark the POI for recognition and processing by the proteasome.

The target protein is subsequently broken down into peptides, while the PROTAC itself can be released and participate in another degradation cycle. This catalytic behavior distinguishes PROTACs from many occupancy-driven inhibitors and creates the possibility of degrading multiple target-protein molecules with comparatively small amounts of degrader.

Advantages Over Traditional Inhibitors

One of the most important attractions of targeted protein degradation is its event-driven pharmacology. A conventional inhibitor generally needs to remain associated with its target to maintain pharmacological activity. A degrader instead initiates a biological event—target ubiquitination and destruction—and the resulting loss of protein can persist after the degrader has moved on.

This catalytic concept can potentially produce sustained biological effects without requiring continuous high target occupancy. However, degradation efficiency remains dependent on factors such as target abundance, E3 expression, ternary-complex formation and cellular context.

TPD may also provide a strategy for addressing some forms of drug resistance. In oncology, mutations can alter an inhibitor-binding pocket while leaving the broader protein architecture and degradation machinery accessible. Protein degraders therefore offer a different route to suppressing resistant disease biology, although resistance to degraders can also emerge through changes in target expression, E3 machinery, drug transport or other cellular mechanisms.

Perhaps the most widely discussed opportunity is the ability to address proteins that lack conventional enzymatic pockets. Transcription factors, scaffolding proteins and regulatory proteins can be difficult to inhibit directly, but a degrader does not necessarily need to block an active site. It needs a productive interaction that enables the cellular degradation machinery to eliminate the target.

Expanding Clinical Pipeline and Therapeutic Applications

The clinical development of targeted protein degradation has moved beyond proof-of-concept. As of 2026, the field includes numerous investigational degraders, and importantly, a PROTAC has now crossed the regulatory approval milestone.

In May 2026, the U.S. Food and Drug Administration approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression after at least one line of endocrine therapy. FDA describes vepdegestrant as a heterobifunctional protein degrader, making the approval an important clinical validation for PROTAC technology. FDA approval of vepdegestrant

The approval is particularly notable because estrogen-receptor degradation has been an important clinical testing ground for TPD. PROTAC-based estrogen receptor degraders are designed to remove the receptor rather than simply modulate its activity, potentially offering another strategy for tumors that have developed resistance to endocrine therapies.

Androgen receptor degradation has similarly been investigated extensively in prostate cancer, including metastatic castration-resistant disease. Earlier clinical-stage programs helped establish the feasibility of targeting hormone receptors through degradation rather than conventional inhibition.

Beyond oncology, researchers are exploring whether degradation technologies can address proteins involved in neurodegeneration, inflammatory disease and other conditions. Programs directed toward neurological targets are beginning to provide clinical data, while approaches involving pathological proteins such as tau and alpha-synuclein remain an active research area. The broader TPD landscape is also expanding toward immune regulation and other disease mechanisms.

Pharmacokinetic Challenges and Delivery Hurdles

The same molecular architecture that gives PROTACs their biological versatility can create pharmaceutical-development problems.

Many PROTACs are substantially larger and more flexible than conventional oral small molecules. Their physicochemical characteristics can extend beyond traditional Lipinski Rule of Five space, creating challenges with membrane permeability, solubility, absorption, distribution and metabolic stability. Recent pharmaceutical research continues to identify poor permeability and oral bioavailability as important barriers to clinical translation.

Oral exposure is particularly challenging because a degrader must reach the appropriate intracellular compartment at concentrations sufficient to engage both the target and E3 ligase. Rapid metabolism or clearance can further reduce effective exposure.

Another distinctive phenomenon is the hook effect. At excessively high concentrations, degradation can decline because excessive binary binding of the individual components interferes with productive ternary-complex formation. Therefore, increasing dose does not necessarily produce proportionally greater degradation.

These properties make formulation, medicinal chemistry, pharmacokinetics and pharmacodynamic modeling central parts of PROTAC development rather than downstream considerations.

Next-Gen Innovations: Molecular Glues and Beyond

The limitations of large bifunctional degraders have helped drive interest in molecular glues. Unlike PROTACs, molecular glue degraders are generally smaller molecules that induce or stabilize an interaction between an E3 ligase and a target protein without requiring a conventional bifunctional linker architecture.

Rather than independently binding two proteins through two connected ligands, a molecular glue can create a new protein–protein interaction surface and promote recruitment of a previously unrecognized substrate. This mechanism can provide drug-like properties that are difficult to achieve with large PROTAC molecules, although rational discovery and optimization of molecular glues remains challenging.

The next generation of TPD research is also looking beyond the small set of E3 ligases traditionally used in degrader development. The human genome contains hundreds of E3 ligases, yet only a limited fraction have been successfully exploited for therapeutic degradation. Expanding this repertoire could allow researchers to design degraders with greater tissue, cell-type or disease-state selectivity.

Other innovations include tissue-targeted delivery, photoactivatable degraders and alternative proximity-based degradation systems. Research published in 2026 also illustrates continued efforts to discover new molecular-glue mechanisms and E3–substrate relationships.

Practical Considerations for Developing or Sourcing TPD Assets

For researchers, biotechnology companies and pharmaceutical developers evaluating a TPD program, the molecular mechanism is only one part of the assessment.

A practical diligence checklist should include:

• E3 ligase selection: Determine whether the selected E3 ligase is sufficiently expressed in the intended target tissue and whether its biology creates a manageable safety profile.
• Linker optimization: Assess whether linker length, flexibility, attachment site and chemical composition support a productive ternary complex rather than simply strong binary binding.
• Degradation kinetics: Review DC50 values alongside Dmax, degradation rate, duration of effect and target resynthesis. A low DC50 alone does not establish therapeutic potential.
• ADME/PK: Examine permeability, metabolic stability, plasma exposure, tissue distribution, clearance and oral bioavailability early rather than treating these properties as late-stage optimization problems.
• Functional validation: Confirm that target degradation produces the intended cellular phenotype and disease-relevant biological response.
• Biomarker strategy: Establish how target engagement and degradation will be measured in vivo and, ultimately, in clinical samples.

For organizations sourcing external TPD assets, these criteria should be combined with patent position, manufacturing complexity, translational evidence and the maturity of the underlying degrader platform.

Evaluating TPD Platform Potential: An Example Framework

A structured evaluation matrix can help pharmaceutical and biotech teams compare PROTAC or molecular-glue programs without relying on a single potency measurement.

Ternary complex stability and affinity receive substantial weight because productive degradation depends on more than target binding alone. E3 ligase selectivity and tissue distribution are important for understanding both efficacy and potential toxicity.

Pharmacokinetic performance should be considered alongside degradation pharmacodynamics: a highly active molecule with inadequate exposure may have limited therapeutic value. Intellectual-property analysis is particularly important in a field where specific warheads, E3 ligands and linker strategies can be covered by overlapping patent estates.

Finally, a strong translational biomarker strategy can determine whether preclinical degradation translates into measurable target engagement in patients.

These weightings are illustrative rather than universal. An early discovery program may emphasize chemistry and ternary-complex biology, while a clinical-stage asset may require greater emphasis on human pharmacology, safety, biomarkers and freedom to operate.

Pitfalls and Red Flags in TPD Development

Protein degradation programs can generate impressive laboratory data while still facing major translational risks.

A pronounced hook effect is one warning sign. If degradation falls sharply at higher concentrations, researchers need to understand whether the apparent potency window will remain therapeutically useful in vivo.

Another concern is unintended degradation. A promiscuous E3 interaction or insufficient target selectivity can potentially affect proteins beyond the intended POI. Comprehensive proteomic profiling can therefore be valuable when evaluating selectivity.

Poor metabolic stability is another common problem. Rapid clearance may prevent adequate intracellular exposure even when cellular assays show strong degradation.

Intellectual property deserves equal attention. Popular target warheads, E3 ligands and linker configurations can sit within crowded patent landscapes, making freedom-to-operate analysis essential before substantial development investment.

Finally, target degradation should not automatically be equated with therapeutic efficacy. A program can achieve impressive DC50 and Dmax values without producing the desired functional rescue if the target is not sufficiently causal for the disease phenotype. The strongest programs connect molecular degradation to cellular function, animal pharmacology and disease-relevant biomarkers.

Final Thoughts — The Permanent Evolution of Protein Control

Targeted protein degradation has developed from an unconventional chemical-biology concept into a clinically validated drug-development strategy. The FDA’s 2026 approval of vepdegestrant provides an important regulatory milestone for PROTAC-based therapeutics, while molecular glues and newer degradation modalities continue to broaden the field.

The next challenge is less about proving that proteins can be degraded and more about controlling where, when and how efficiently degradation occurs. Better E3 ligases, smarter molecular designs, improved delivery and stronger translational biomarkers could determine how widely TPD is applied beyond current targets and therapeutic areas.

The fundamental shift remains powerful: instead of asking how to inhibit a problematic protein, drug developers can increasingly ask whether the protein needs to exist at all.